Developer docs
API playgroundTry for free, no card

Search company profiles

Upcyte Technologies

Full company profile

uuid000h83v

Namestring
Upcyte Technologies
Legal namestring
Upcyte Technologies
Websiteurl
upcyte.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Upcyte Technologies is a Germany-based life science company founded in 2015 that develops and commercialises expanded human primary cells for research and in vitro diagnostic applications. Its core proprietary upcyte® technology uses a viral gene-transfer system to drive primary cells back into controlled proliferation without inducing immortalisation, preserving tissue-specific phenotype and enabling expansion of up to 4,000 vials per cell type and donor from the same source. The product catalogue spans hepatocytes, liver sinusoidal endothelial cells (LSECs), keratinocytes, microvascular endothelial cells, HUVECs, and skeletal muscle cells, complemented by optimised cell-culture media, the SoftXS bioreactor platform for 3D cell culture, and a custom upcyte service to expand customer-supplied primary cells.

The company operates a B2B research-tools model, selling catalog cells directly through an e-commerce platform and via the parent CLINISCIENCES GROUP's worldwide distributor network, alongside custom services (the upcyte® service and ixcyte® lentiviral cell-line customisation). Target customers are pharmaceutical and biotechnology companies engaged in drug discovery, metabolism, toxicity, and viral infection research, academic and research institutions, and (to a lesser extent) IVD laboratories. Pricing is quote-based and not publicly disclosed, and standard vial formats are 1–5 million cells.

Upcyte Technologies is a subsidiary of the CLINISCIENCES GROUP, which holds ISO 13485:2016 certification covering the group's quality management system. Upcyte® hepatocytes and endothelial cells are classified as Risk Group 1 genetically modified organisms by the German Federal Office of Consumer Protection and Food Safety (BVL) and the Central Committee on Biological Safety (ZKBS), permitting handling at Security Level 1 genetic engineering facilities. The company's primary operating address is 74 Rue des Suisses, 92000 Nanterre, France, with German phone contact, indicating a France–Germany dual operating footprint.

Short descriptiontext

Upcyte Technologies is a Germany-based life science company that produces expanded human primary cells (hepatocytes, LSECs, keratinocytes, mvECs, HUVECs, skeletal muscle) via proprietary upcyte viral gene-transfer technology for pharma R&D, academic, and IVD laboratory customers through direct and distributor channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHamburg, Germany
HQ citystring
Hamburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
primary cell expansion, human cell biology, cell culture products, life science reagents, in vitro research tools
Industry2 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Culture Products
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Expanded Primary Cells
TypeOne Time License
Description

Sale of cryopreserved, assay-ready expanded primary cells including hepatocytes, liver sinusoidal endothelial cells, keratinocytes, and other cell types. Cells are available in standard formats (1-5 million cells per vial) and can be expanded to up to 4000 vials per cell type per donor.

upcyte.com
2Custom Cell Services
TypeProfessional Services
Description

Custom upcyting services where customers provide their own primary cells, which are then expanded using the upcyte technology and shipped back as cryopreserved vials or stored at the facility.

upcyte.com
3Cell Culture Media and Reagents
TypeHardware Sales
Description

Sale of optimized medium formulations and complementary reagents for cell culture applications.

upcyte.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1upcyte®
Description

Expanded primary cells produced using proprietary technology that drives non-dividing primary cells back into proliferation via viral gene transfer without altering tissue-specific characteristics. Cells available from various human tissues with optimized medium formulations.

upcyte.com
+1 more record
Core offering1 text field

Upcyte Technologies manufactures and sells expanded primary human cells (hepatocytes, liver sinusoidal endothelial cells, keratinocytes, microvascular endothelial cells, HUVECs, and skeletal muscle cells) using its proprietary upcyte technology based on viral gene transfer for controlled cell proliferation. The company also provides custom cell line development services, cell culture media and reagents, and the SoftXS bioreactor platform to pharmaceutical, biotechnology, and academic research customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 4000 vials per cell type per donor
+2 more records
Product overview1 text field

Upcyte Technologies offers a portfolio of expanded primary cells and custom cell services for research and in vitro diagnostics. The core product line includes upcyte® expanded primary cells—human cells driven back into proliferation via viral gene transfer while retaining primary phenotypic characteristics. Key products include hepatocytes, liver sinusoidal endothelial cells (LSECs), keratinocytes, microvascular endothelial cells, HUVECs, and skeletal muscle cells. The company also provides SoftXS, a scalable bioreactor platform for 3D cell culture. Two complementary services support the product portfolio: upcyte® service enables custom expansion of customer-provided primary cells, while ixcyte® provides custom cell line development using lentiviral technology. Support products include optimized cell culture media and ConTaFree disinfectant products for laboratory sterility.

Product and service1 record
1upcyte Hepatocytes
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dynamic42 is a biotech company specialized in human in vitro organ-on-chip models. Upcyte collaborates with Dynamic42 on webinars and liver toxicity research, combining expertise in cell culture and organ-on-chip technology. The collaboration showcases how upcyte expanded primary cells (LSECs and hepatocytes) can be used in advanced liver organ models for hepatotoxicity testing.

Strategic tierMinorTypeOthers
Description

OVH SAS is the hosting provider for upcyte.com website, providing cloud infrastructure services from their Roubaix, France data center.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

InSphero develops 3D organoid and organ-on-chip models for drug discovery, including liver and toxicology applications that directly overlap with Upcyte's hepatocyte and LSEC use cases. It represents the next-generation in vitro model platform Upcyte could supply into.

TypeDirect peer
Description

CellGenix manufactures cell culture reagents and primary cells for cell therapy and translational research. It is comparable in being a smaller specialty player serving pharma/biotech and academic research with cell-based products.

3Merck KGaA / MilliporeSigma
TypeBroad incumbent
Description

MilliporeSigma supplies primary cells, cell lines, and culture reagents across life sciences research and bioprocessing. It competes with Upcyte's catalog cell and media offering while also serving much larger pharma manufacturing customers.

TypeDirect peer
Description

STEMCELL Technologies provides primary cells, cell culture media, and specialized reagents for academic and pharma research. It is a direct competitor in primary-cell catalog sales with comparable target customers.

5Corning Life Sciences
TypeBroad incumbent
Description

Corning supplies cell culture vessels, media, surfaces, and bioprocess products that compete with the broader Upcyte product portfolio, particularly the SoftXS bioreactor platform and culture media.

TypeBroad incumbent
Description

Lonza is a major contract manufacturer and supplier of primary cells, cell lines, and cell-culture media across pharma and biotech. It overlaps with Upcyte in primary hepatocytes and endothelial cells but operates at vastly greater scale and breadth.

TypeDirect peer
Description

PromoCell supplies human primary cells and optimized cell culture media for research and drug discovery. It is a direct competitor in the primary-cell catalog market, serving overlapping pharma/biotech and academic customers with similar cell types (hepatocytes, endothelial, keratinocytes).

TypeBroad incumbent
Description

Bio-Techne (R&D Systems, Tocris) supplies primary cells, cytokines, and reagents across research and applied markets. It competes with Upcyte's primary-cell catalog and media/reagents at the high end of the research-tools spectrum.

TypeBroad incumbent
Description

ATCC supplies authenticated cell lines, primary cells, and biological materials to research and clinical labs globally. It competes with Upcyte's cell catalog but with a much broader mandate including cell line authentication services.

TypeBroad incumbent
Description

Gibco supplies primary cells, cell culture media, and reagents to research and pharma customers globally. It competes with Upcyte across nearly all of Upcyte's product categories but from a much broader portfolio position.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Upcyte Technologies

Cell Culture Productsupcyte.com

Upcyte Technologies is a Germany-based life science company that produces expanded human primary cells (hepatocytes, LSECs, keratinocytes, mvECs, HUVECs, skeletal muscle) via proprietary upcyte viral gene-transfer technology for pharma R&D, academic, and IVD laboratory customers through direct and distributor channels.

What Upcyte Technologies does

Upcyte Technologies is a Germany-based life science company founded in 2015 that develops and commercialises expanded human primary cells for research and in vitro diagnostic applications. Its core proprietary upcyte® technology uses a viral gene-transfer system to drive primary cells back into controlled proliferation without inducing immortalisation, preserving tissue-specific phenotype and enabling expansion of up to 4,000 vials per cell type and donor from the same source. The product catalogue spans hepatocytes, liver sinusoidal endothelial cells (LSECs), keratinocytes, microvascular endothelial cells, HUVECs, and skeletal muscle cells, complemented by optimised cell-culture media, the SoftXS bioreactor platform for 3D cell culture, and a custom upcyte service to expand customer-supplied primary cells.

The company operates a B2B research-tools model, selling catalog cells directly through an e-commerce platform and via the parent CLINISCIENCES GROUP's worldwide distributor network, alongside custom services (the upcyte® service and ixcyte® lentiviral cell-line customisation). Target customers are pharmaceutical and biotechnology companies engaged in drug discovery, metabolism, toxicity, and viral infection research, academic and research institutions, and (to a lesser extent) IVD laboratories. Pricing is quote-based and not publicly disclosed, and standard vial formats are 1–5 million cells.

Upcyte Technologies is a subsidiary of the CLINISCIENCES GROUP, which holds ISO 13485:2016 certification covering the group's quality management system. Upcyte® hepatocytes and endothelial cells are classified as Risk Group 1 genetically modified organisms by the German Federal Office of Consumer Protection and Food Safety (BVL) and the Central Committee on Biological Safety (ZKBS), permitting handling at Security Level 1 genetic engineering facilities. The company's primary operating address is 74 Rue des Suisses, 92000 Nanterre, France, with German phone contact, indicating a France–Germany dual operating footprint.

Upcyte Technologies firmographics

Firmographics
Name
Upcyte Technologies
Legal name
Upcyte Technologies
Website
https://upcyte.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Upcyte Technologies is a Germany-based life science company that produces expanded human primary cells (hepatocytes, LSECs, keratinocytes, mvECs, HUVECs, skeletal muscle) via proprietary upcyte viral gene-transfer technology for pharma R&D, academic, and IVD laboratory customers through direct and distributor channels.
Ownership category
akta.pro rank

Upcyte Technologies industry classification

Industry
Product category
Cell Culture Products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Primary cell expansion
  • Human cell biology
  • Cell culture products
  • Life science reagents
  • In vitro research tools

Where Upcyte Technologies is headquartered

Location

Headquarters

HQ city
Hamburg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Upcyte Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Expanded Primary Cells: Sale of cryopreserved, assay-ready expanded primary cells including hepatocytes, liver sinusoidal endothelial cells, keratinocytes, and other cell types. Cells are available in standard formats (1-5 million cells per vial) and can be expanded to up to 4000 vials per cell type per donor.
  2. Custom Cell Services: Custom upcyting services where customers provide their own primary cells, which are then expanded using the upcyte technology and shipped back as cryopreserved vials or stored at the facility.
  3. Cell Culture Media and Reagents: Sale of optimized medium formulations and complementary reagents for cell culture applications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Upcyte Technologies product offering

Product offering

Core offering

Upcyte Technologies manufactures and sells expanded primary human cells (hepatocytes, liver sinusoidal endothelial cells, keratinocytes, microvascular endothelial cells, HUVECs, and skeletal muscle cells) using its proprietary upcyte technology based on viral gene transfer for controlled cell proliferation. The company also provides custom cell line development services, cell culture media and reagents, and the SoftXS bioreactor platform to pharmaceutical, biotechnology, and academic research customers.

Product overview

Upcyte Technologies offers a portfolio of expanded primary cells and custom cell services for research and in vitro diagnostics. The core product line includes upcyte® expanded primary cells—human cells driven back into proliferation via viral gene transfer while retaining primary phenotypic characteristics. Key products include hepatocytes, liver sinusoidal endothelial cells (LSECs), keratinocytes, microvascular endothelial cells, HUVECs, and skeletal muscle cells. The company also provides SoftXS, a scalable bioreactor platform for 3D cell culture. Two complementary services support the product portfolio: upcyte® service enables custom expansion of customer-provided primary cells, while ixcyte® provides custom cell line development using lentiviral technology. Support products include optimized cell culture media and ConTaFree disinfectant products for laboratory sterility.

Differentiator

Problem solved

Functional benefit

Brands

  • upcyte®: Expanded primary cells produced using proprietary technology that drives non-dividing primary cells back into proliferation via viral gene transfer without altering tissue-specific characteristics. Cells available from various human tissues with optimized medium formulations.
  • ixcyte®

Products and services

  • upcyte Hepatocytes

Quantifiable outcome

  • Up to 4000 vials per cell type per donor
  • +2 more outcomes

Companies that use Upcyte Technologies

Customer profile

Segments3 records

Ideal customer profiles3 records

Upcyte Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Upcyte Technologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Dynamic42coreStrategic or Co-development PartnerDynamic42 is a biotech company specialized in human in vitro organ-on-chip models. Upcyte collaborates with Dynamic42 on webinars and liver toxicity research, combining expertise in cell culture and organ-on-chip technology. The collaboration showcases how upcyte expanded primary cells (LSECs and hepatocytes) can be used in advanced liver organ models for hepatotoxicity testing.
  • OVH SASminorOthersOVH SAS is the hosting provider for upcyte.com website, providing cloud infrastructure services from their Roubaix, France data center.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Upcyte Technologies competitors and assessment

Company assessment

Emerging players

  • InSphero: InSphero develops 3D organoid and organ-on-chip models for drug discovery, including liver and toxicology applications that directly overlap with Upcyte's hepatocyte and LSEC use cases. It represents the next-generation in vitro model platform Upcyte could supply into.

Direct peers

  • CellGenix: CellGenix manufactures cell culture reagents and primary cells for cell therapy and translational research. It is comparable in being a smaller specialty player serving pharma/biotech and academic research with cell-based products.
  • STEMCELL Technologies: STEMCELL Technologies provides primary cells, cell culture media, and specialized reagents for academic and pharma research. It is a direct competitor in primary-cell catalog sales with comparable target customers.
  • PromoCell: PromoCell supplies human primary cells and optimized cell culture media for research and drug discovery. It is a direct competitor in the primary-cell catalog market, serving overlapping pharma/biotech and academic customers with similar cell types (hepatocytes, endothelial, keratinocytes).

Broad incumbents

  • Merck KGaA / MilliporeSigma: MilliporeSigma supplies primary cells, cell lines, and culture reagents across life sciences research and bioprocessing. It competes with Upcyte's catalog cell and media offering while also serving much larger pharma manufacturing customers.
  • Corning Life Sciences: Corning supplies cell culture vessels, media, surfaces, and bioprocess products that compete with the broader Upcyte product portfolio, particularly the SoftXS bioreactor platform and culture media.
  • Lonza: Lonza is a major contract manufacturer and supplier of primary cells, cell lines, and cell-culture media across pharma and biotech. It overlaps with Upcyte in primary hepatocytes and endothelial cells but operates at vastly greater scale and breadth.
  • Bio-Techne: Bio-Techne (R&D Systems, Tocris) supplies primary cells, cytokines, and reagents across research and applied markets. It competes with Upcyte's primary-cell catalog and media/reagents at the high end of the research-tools spectrum.
  • ATCC: ATCC supplies authenticated cell lines, primary cells, and biological materials to research and clinical labs globally. It competes with Upcyte's cell catalog but with a much broader mandate including cell line authentication services.
  • Thermo Fisher Scientific (Gibco): Gibco supplies primary cells, cell culture media, and reagents to research and pharma customers globally. It competes with Upcyte across nearly all of Upcyte's product categories but from a much broader portfolio position.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Upcyte Technologies social profiles

Digital presence

Upcyte Technologies compliance and trust

Trust signal

Compliance1 record

Upcyte Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Upcyte Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Upcyte Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Upcyte Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Upcyte Technologies

What does Upcyte Technologies do?

Upcyte Technologies manufactures and sells expanded primary human cells (hepatocytes, liver sinusoidal endothelial cells, keratinocytes, microvascular endothelial cells, HUVECs, and skeletal muscle cells) using its proprietary upcyte technology based on viral gene transfer for controlled cell proliferation. The company also provides custom cell line development services, cell culture media and reagents, and the SoftXS bioreactor platform to pharmaceutical, biotechnology, and academic research customers.

Is Upcyte Technologies a public or private company?

Upcyte Technologies is a private company. It is classified as corporate owned and is currently operating.

When was Upcyte Technologies founded?

Upcyte Technologies was founded in 2015. It employs 1 to 10 people.

Where is Upcyte Technologies based?

Upcyte Technologies is headquartered in Hamburg, Germany, in the Europe region.

How does Upcyte Technologies make money?

Three revenue lines are on record. Expanded Primary Cells are the primary driver. The others are custom Cell Services and cell Culture Media and Reagents.

Who are Upcyte Technologies's main competitors?

InSphero is listed as an emerging player. Direct peers are CellGenix, STEMCELL Technologies and PromoCell. Broad incumbents are Merck KGaA / MilliporeSigma, Corning Life Sciences, Lonza, Bio-Techne, ATCC and Thermo Fisher Scientific (Gibco).

Does Upcyte Technologies have an API?

No public API is recorded for Upcyte Technologies.

What industry is Upcyte Technologies in?

Upcyte Technologies's product category is Cell Culture Products. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales